Generative AI | Machine Learning | AI Infrastructure | Regional Breakdown | March 2026 | Source: MRFR

 

$1.85T Market Value by 2032

36.8% CAGR (2024–2032)

$196B Market Value in 2024

 

Overview

Artificial Intelligence Market  global Artificial Intelligence Market is projected to grow from USD 196 billion in 2024 to USD 1.85 trillion by 2032, registering a 36.8% CAGR — representing the fastest capital compounding in any technology market segment in recorded economic history. The convergence of foundational model capability, AI infrastructure CapEx acceleration, enterprise software AI integration, autonomous agent deployment, and the proliferation of AI-native applications across every industry vertical is establishing artificial intelligence as the defining general-purpose technology of the 21st century.

Key Takeaways

• The global Artificial Intelligence Market is projected to reach USD 1.85 trillion by 2032 at a 36.8% CAGR.
• Generative AI alone represents a USD 1.3 trillion revenue opportunity by 2032, according to Goldman Sachs research projections.
• Hyperscalers (AWS, Azure, GCP, Meta) committed USD 320 billion in AI infrastructure CapEx in 2025 alone.
• AI software (applications, platforms, APIs) will account for 68% of total AI market revenue by 2032 versus 32% for infrastructure.
• Enterprise AI adoption has reached 78% of Fortune 500 companies in 2025, up from 34% in 2022.

 

Segment & Technology Breakdown

Technology / Segment	Primary Buyer	Key Driver	Outlook
Generative AI (LLMs, Image, Video)	All Segments	Content creation, code, reasoning	Fastest-growing; USD 1.3T by 2032
AI Infrastructure (GPU, Cloud)	Hyperscalers, Enterprises	Model training, inference at scale	Capital-intensive; NVIDIA dominant
AI Software & APIs	Developers, Enterprises	Application integration, AI-as-a-service	Highest revenue share; 68% by 2032
AI in Healthcare & Life Sciences	Hospitals, Pharma, Biotech	Drug discovery, diagnostics, genomics	High-impact; clinical validation wave
Autonomous AI Agents	Enterprise, Consumer	Multi-step task automation, workflows	Emerging; 52%+ CAGR sub-category

 

What Is Driving Demand?

Foundational Model Capability & Accessibility

The release of GPT-4, Claude 3, Gemini Ultra, and open-source Llama 3/Mistral models has democratised access to human-parity reasoning, multimodal analysis, and code generation capabilities through API-first consumption models at costs declining 90% per token since 2023. Developer access to frontier AI capabilities via simple REST API calls has compressed AI application development from years to weeks — catalysing an application layer explosion that is the primary revenue growth engine for the USD 1.85 trillion AI market.

AI Infrastructure CapEx Acceleration

Hyperscaler AI data centre CapEx commitments of USD 320 billion in 2025 (Amazon USD 100B, Microsoft USD 80B, Google USD 75B, Meta USD 65B) are driven by AI training and inference workload demand that is growing faster than GPU supply. NVIDIA’s 95%+ AI accelerator market share, AMD’s MI300X ramp, and custom silicon programmes (Google TPU v5, AWS Trainium, Microsoft Maia) are creating a USD 400+ billion annual AI infrastructure market by 2027 — the largest capital investment cycle in technology history.

Enterprise AI Software Integration

The integration of AI capabilities across enterprise software stacks (Microsoft 365 Copilot, Salesforce Einstein, ServiceNow AI, SAP Joule, Oracle AI) is creating SaaS platform upgrade cycles where AI feature tiers command 30–85% premium pricing over base subscriptions. Enterprise AI software ACV is growing at 42% CAGR as AI becomes the primary competitive differentiation axis in every enterprise software category, from ERP to CRM to DevOps.

AI in Regulated Industries: Healthcare, Finance & Legal

Healthcare AI (diagnostic imaging, drug discovery, clinical documentation), financial AI (algorithmic trading, credit underwriting, fraud detection), and legal AI (contract analysis, discovery automation, compliance monitoring) are generating measurable ROI that is driving regulated industry AI investment at 28–38% CAGR — with FDA AI/ML software clearances reaching 950+ by 2025 and financial regulators establishing AI governance frameworks that legitimise enterprise deployment.

AI-Native Application & Vertical SaaS Proliferation

AI-native vertical SaaS companies (Harvey AI for legal, Abridge for clinical documentation, Observe.AI for contact centres, Cohere for enterprise NLP) are displacing legacy software incumbents in professional services markets by delivering 3–8x better unit economics and workflow automation depth versus bolted-on AI features — creating a USD 280 billion AI-native vertical software market by 2028.

 

Get the full data — free sample available: → Download Free Sample PDF  |  Includes market sizing, segmentation methodology & regional forecast tables.

 

KEY INSIGHT: McKinsey Global Institute estimates that AI could add USD 4.4 trillion annually to the global economy through productivity gains — with knowledge work (software engineering, marketing, customer service, finance, legal) capturing 75% of that value through task automation and augmentation. Enterprises achieving full AI integration across their core business workflows report 22–38% operating cost reductions and 2.1x revenue growth rates versus AI-laggard competitors in the same industry vertical.

 

Regional Market Breakdown

Region	Maturity	Key Drivers	Outlook
North America	Dominant	Hyperscaler CapEx, frontier model labs, enterprise AI adoption leadership	Dominant; model + infrastructure + apps
Europe	Mature	EU AI Act compliance, enterprise AI adoption, GDPR-compliant AI	Strong; regulatory-grade AI differentiation
Asia-Pacific	Fastest Growing	China AI investment (Baidu, Alibaba, DeepSeek), India IT+AI, Japan robotics AI	Highest CAGR; sovereign AI competition
Middle East	Fast-Growing	UAE NADIA, Saudi Public Investment Fund AI, Falcon LLM, sovereign AI	Accelerating; government-backed AI scale
Latin America	Emerging	Brazil AI ecosystem, Mexico nearshore AI services, regional AI adoption	Growing; enterprise AI early adoption

 

Competitive Landscape

The AI market is led by NVIDIA (infrastructure), Microsoft (enterprise AI platform), Google/Alphabet (Gemini/cloud AI), Amazon (AWS AI/Bedrock), Meta (open-source AI), OpenAI, Anthropic, xAI, and enterprise AI software leaders including Salesforce, ServiceNow, and Oracle. Foundational model capability, AI infrastructure supply chain, enterprise integration depth, and open-source ecosystem contribution are primary competitive differentiators.

Outlook Through 2032

The Artificial Intelligence Market through 2032 will be defined by agentic AI achieving reliable autonomous enterprise workflow execution, multimodal AI becoming the universal application interface, AI-native vertical SaaS displacing legacy incumbents across professional services markets, and sovereign AI investment creating regional competitive dynamics that reshape the global technology industry. Companies investing in proprietary training data, foundational model research, AI infrastructure capacity, and enterprise-grade deployment security will define category leadership as AI transitions from experimental technology to essential business operating infrastructure.

 

Access complete forecasts, segment analysis & competitive intelligence: Full Report: → Purchase the Full Artificial Intelligence Market Report (2025–2032) Free Sample PDF: Request Free Sample

 

Source: Market Research Future (MRFR) | All market projections are forward-looking estimates and subject to revision. © MRFR · marketresearchfuture.com

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global AI/ML and Computational Tools in RNA Research and Therapeutics Market Size, Share & Trends Analysis Report By Technologies and Processes (RNA Design and Sequence Optimization, RNA Delivery Systems, RNA Sequencing and Data Analysis, Target Identification and Validation, Preclinical and Clinical Development Tools, Hardware and Infrastructure Support), Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, Other Therapeutics), End-User (Pharmaceutical and Biotech Companies, Academic and Research Institutions, Contract Research Organizations (CROs), Healthcare Providers (Emerging))- Market Outlook And Industry Analysis 2034″

Global AI/ML and Computational Tools in RNA Research and Therapeutics Market Size is predicted to develop at an 26.8% CAGR during the forecast period for 2025-2034.

 

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2974

 

Artificial Intelligence (AI), Machine Learning (ML), and advanced computational platforms are playing an increasingly critical role in the progression of RNA research and the development of RNA-based therapeutics. These technologies enable the analysis of complex biological systems, facilitating a deeper understanding of RNA functions and accelerating the discovery and refinement of RNA-targeted therapeutic solutions. Given the central role of RNA in cellular processes, the integration of AI and ML is essential for advancing insights into RNA structure, function, and molecular interactions.

Leveraging large-scale data analytics, AI and ML support key processes such as RNA structure prediction, identification of disease-specific targets, optimization of nucleotide sequences, and the development of therapeutic modalities, including messenger RNA (mRNA) vaccines, small interfering RNAs (siRNAs), and antisense oligonucleotides (ASOs). Advanced computational tools—comprising specialized algorithms, bioinformatics platforms, and curated biological datasets—enhance efficiency across workflows related to data interpretation, target validation, and drug discovery.

Core applications include the prediction of RNA secondary and tertiary structures, the use of graph-based methodologies such as diffusion-based models for target identification, and the deployment of AI-driven platforms to accelerate therapeutic development. In addition, AI and ML contribute to advancements in RNA sequencing analysis and support precision medicine initiatives by enabling biomarker discovery and facilitating personalized treatment approaches. By addressing challenges associated with complex biological data and limited structural insights, these technologies are driving innovation in RNA therapeutics and expanding their potential applications across a wide range of disease areas.

 

Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/aiml-and-computational-tools-in-rna-research-and-therapeutics-market/2974

 

List of Prominent Players in the AI/ML and Computational Tools in RNA Research and Therapeutics Market:

• Deep Genomics
• Insilico Medicine
• Atomwise
• Schrödinger
• Generate Biomedicines
• e-therapeutics
• NVIDIA
• Illumina
• Relation Therapeutics
• BenevolentAI
• Fluence Technologies
• Satija Lab

Market Dynamics

Drivers:

The integration of Artificial Intelligence (AI), Machine Learning (ML), and advanced computational platforms in RNA research and therapeutics is being driven by rapid progress in RNA biology, the expansion of high-throughput sequencing data, and the increasing need for efficient and cost-effective drug discovery approaches. These technologies facilitate accelerated target identification, support the development of RNA-based therapies—including messenger RNA (mRNA) vaccines and small interfering RNAs (siRNAs)—and enable precision medicine through data-driven patient segmentation.

As RNA therapeutics are increasingly applied to complex and multifactorial diseases, continuous advancements in AI algorithms and bioinformatics tools are enhancing the accuracy, scalability, and efficiency of research and development processes. In addition, sustained investments and collaborative efforts among academic institutions, research organizations, and industry participants are further advancing innovation within this domain.

Challenges:

Despite their significant potential, the application of AI and ML in RNA therapeutics is associated with several challenges. Variability and inconsistency in experimental datasets can affect the accuracy and reliability of predictive models. The inherent complexity of RNA biology—characterized by diverse structural configurations and dynamic regulatory mechanisms—makes it difficult to establish consistent relationships between RNA sequences and functional outcomes. Furthermore, challenges related to therapeutic delivery, including molecular instability, limited cellular uptake, and size-related constraints, continue to hinder the clinical translation and effectiveness of RNA-based therapies.

Regional Trends:

North America currently holds a leading position in the AI- and ML-driven RNA therapeutics market, supported by a strong presence of pharmaceutical and biotechnology companies such as Pfizer, Moderna, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals. The region benefits from a supportive regulatory framework, with the U.S. Food and Drug Administration (FDA) offering expedited pathways such as Fast Track and Breakthrough Therapy designations to accelerate the development of RNA-based treatments. Additionally, North America’s advanced research infrastructure—including high-throughput genomic sequencing technologies, high-performance computing capabilities, and specialized laboratory facilities—enables effective integration of AI and ML into RNA-focused drug discovery and development processes.

 

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

 

Recent Developments:

• In July 2024, Schrödinger launched an initiative to enhance early toxicology prediction in drug discovery using its physics-based platform and NVIDIA’s AI, aiming to reduce safety-related failures and speed up development—aligning with the FDA’s Predictive Toxicology Roadmap.
• In Sep 2023, Deep Genomics unveiled its AI foundation model, BigRNA, through a new manuscript highlighting its ability to predict tissue-specific RNA regulation, protein/microRNA binding sites, and therapeutic effects. Unlike task-specific tools, BigRNA enables broad biological discovery and identification of novel RNA therapeutics, marking a significant advance in AI-driven drug development.

Segmentation of Trusted Platform Module Market-

By Technologies and Processes:

• RNA Design and Sequence Optimization
• RNA Delivery Systems
• RNA Sequencing and Data Analysis
• Target Identification and Validation
• Preclinical and Clinical Development Tools
• Hardware and Infrastructure Support

By Product:

• Vaccines
• Drugs

By Type:

• mRNA Therapeutics
• RNA Interference (RNAi) Therapeutics
• Antisense Oligonucleotide (ASO) Therapeutics
• Other Therapeutics

By End-User:

• Pharmaceutical and Biotech Companies
• Academic and Research Institutions
• Contract Research Organizations (CROs)
• Healthcare Providers (Emerging)

By Region-

North America-

• The US
• Canada

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Mexico
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa

 

Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customisation/2974

 

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:

InsightAce Analytic Pvt. Ltd.

Visit: https://www.insightaceanalytic.com/

Tel : +1 607 400-7072

Asia: +91 79 72967118

info@insightaceanalytic.com